Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS, INC. | 2026-04-02 18:26:44 | 1.59 | 0 | -0.01 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LXRX | 0001062822 | LEXICON PHARMACEUTICALS, INC. | US5288723027 | — | 760474169 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 2445 TECHNOLOGY FOREST BLVD. | THE WOODLANDS | TX | 77381 | UNITED STATES | US | 2818633000 | 2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 77381 | 2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 77381 | LEXICON PHARMACEUTICALS, INC./DE | Pharmaceutical | 1995 | — | 225 | http://lexpharma.com | 170,000,000 | 365,848,216 | 423,680,611 | Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. | 2026-04-02 17:43:10 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 170,000,000 | -127,100,000 | -42.7802 | 423,680,611 | 62,188,316 | 17.2032 |
| 2024 | 297,100,000 | 23,400,000 | 8.5495 | 361,492,295 | 115,255,542 | 46.8068 |
| 2023 | 273,700,000 | 139,300,000 | 103.6458 | 246,236,753 | 57,511,010 | 30.4733 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Michael S. Exton, Ph.D. | Chief Executive Officer, Director | 2025 | 650,576 | 483,822 | 1,049,304 | — | 15,020 | 3,553,953 |
| Lonnel Coats | Director, Chief Executive Officer | 2024 | 438,757 | 0 | 1,656,403 | — | 59,507 | 3,512,773 |
| Brian T. Crum | General Counsel, Senior Vice President | 2024 | 473,503 | 125,442 | 447,544 | — | 17,171 | 1,430,607 |
| Craig B. Granowitz, M.D. | Chief Medical Officer, Senior Vice President | 2024 | 501,686 | 199,373 | 478,762 | — | 16,019 | 1,588,383 |
| Alan J. Main, Ph.D. | Executive Vice President | 2024 | 457,802 | 123,372 | 440,170 | — | 14,278 | 1,396,523 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 81 |
| 2024 | 103 |
| 2023 | 285 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 49,803,000 | 31,081,000 | 1,204,000 |
| Cost Of Revenue | 274,000 | 616,000 | 85,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 61,121,000 | 84,480,000 | 58,887,000 |
| General And Administrative Expenses | 37,319,000 | 143,102,000 | 113,982,000 |
| Operating Expenses | 98,714,000 | 228,198,000 | 172,954,000 |
| Operating Income | -48,911,000 | -197,117,000 | -171,750,000 |
| Net Income | -50,341,000 | -200,403,000 | -177,119,000 |
| Earnings Per Share Basic | -0.14 | -0.63 | -0.8 |
| Earnings Per Share Diluted | -0.14 | -0.63 | -0.8 |
| Weighted Average Shares Outstanding Basic | 363,053,000 | 320,031,000 | 221,130,000 |
| Weighted Average Shares Outstanding Diluted | 363,053,000 | 320,031,000 | 221,130,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 34,326,000 | 66,656,000 | 22,465,000 |
| Marketable Securities Current | 61,904,000 | 171,301,000 | 147,561,000 |
| Accounts Receivable | 2,384,000 | 3,473,000 | 1,010,000 |
| Inventories | 281,000 | 231,000 | 381,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 3,000,000 | 4,532,000 | 5,130,000 |
| Total Assets Current | 101,895,000 | 246,193,000 | 176,547,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 1,863,000 | 2,484,000 | 1,987,000 |
| Other Assets Non Current | 368,000 | 368,000 | 828,000 |
| Total Assets Non Current | 83,092,000 | 52,227,000 | 52,882,000 |
| Total Assets | 184,987,000 | 298,420,000 | 229,429,000 |
| Accounts Payable | 3,083,000 | 14,801,000 | 14,389,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 4,595,000 | — | — |
| Other Liabilities Current | 13,189,000 | 30,447,000 | 17,157,000 |
| Total Liabilities Current | 20,867,000 | 45,248,000 | 31,546,000 |
| Long Term Debt | 49,408,000 | 100,298,000 | 99,508,000 |
| Other Liabilities Non Current | 7,174,000 | 6,924,000 | — |
| Total Liabilities Non Current | 56,582,000 | 107,222,000 | 104,773,000 |
| Total Liabilities | 77,449,000 | 152,470,000 | 136,319,000 |
| Common Stock | 366,000 | 363,000 | 245,000 |
| Retained Earnings | -2,017,583,000 | -1,967,242,000 | -1,766,839,000 |
| Accumulated Other Comprehensive Income | 30,000 | 119,000 | 31,000 |
| Total Shareholders Equity | 107,538,000 | 145,950,000 | 93,110,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 621,000 | 534,000 | 554,000 |
| Share Based Compensation Expense | 12,517,000 | 13,499,000 | 14,340,000 |
| Other Non Cash Income Expense | 1,742,000 | -812,000 | — |
| Change In Accounts Receivable | -1,089,000 | 2,463,000 | 982,000 |
| Change In Inventories | 50,000 | -150,000 | 381,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -757,000 | -1,152,000 | -467,000 |
| Change In Accounts Payable | -30,222,000 | 14,801,000 | 6,454,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -67,851,000 | -178,780,000 | -161,897,000 |
| Purchases Of Marketable Securities | 139,838,000 | 328,747,000 | 223,343,000 |
| Sales Of Marketable Securities | 252,858,000 | 314,400,000 | 173,870,000 |
| Acquisition Of Property Plant And Equipment | 0 | 1,031,000 | 470,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 113,020,000 | -15,378,000 | -49,943,000 |
| Tax Withholding For Share Based Compensation | 572,000 | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 0 | 138,823,000 |
| Repurchase Of Common Stock | — | 1,730,000 | 824,000 |
| Issuance Of Long Term Debt | 0 | 0 | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 0 | -1,307,000 | — |
| Cash From Financing Activities | -48,499,000 | 238,349,000 | 187,960,000 |
| Change In Cash | -3,330,000 | 44,191,000 | -23,880,000 |
| Cash At End Of Period | 34,326,000 | 66,656,000 | 22,465,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 8,330,000 | 12,919,000 | 10,057,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.14 | -0.63 | -0.8 |
| Price To Earnings Ratio | -8.2143 | -1.1722 | -1.9125 |
| Earnings Growth Rate | -77.7778 | -21.25 | -165.0407 |
| Price Earnings To Growth Ratio | 0.1056 | 0.0552 | 0.0116 |
| Book Value Per Share | 0.2962 | 0.456 | 0.4211 |
| Price To Book Ratio | 3.8825 | 1.6193 | 3.6336 |
| Ebitda | -49,720,000 | -214,669,000 | -164,965,000 |
| Enterprise Value | 437,187,950 | 269,984,893.5 | 415,371,900 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.5022 | 0.6872 | 1.0687 |
| Capital Expenditures | 0 | 1,031,000 | -11,506,000 |
| Free Cash Flow | -67,851,000 | -179,811,000 | -150,391,000 |
| Return On Equity | -0.4681 | -1.3731 | -1.9023 |
| One Year Beta | 0.8499 | 1.9693 | 1.7188 |
| Three Year Beta | 1.299 | 1.6927 | 1.5543 |
| Five Year Beta | 1.413 | 1.1891 | 1.1606 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Exton Michael | Director, Chief Executive Officer | 2026-02-28 | 503,263 | A | 503,263 |
| Exton Michael | Director, Chief Executive Officer | 2026-02-28 | 204,831 | D | 298,432 |
| Exton Michael | Director, Chief Executive Officer | 2026-02-28 | 503,263 | D | 1,006,527 |
| Coiante Scott M | SVP, Chief Financial Officer | 2026-02-28 | 160,237 | A | 160,237 |
| Coiante Scott M | SVP, Chief Financial Officer | 2026-02-28 | 54,881 | D | 105,356 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 1,059,385 | 921,204 | 1.15 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 385 | 335 | 1.1493 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 169 | 147 | 1.1497 |
| Virtu Financial LLC | 2025-12-31 | 42,000 | 36,468 | 1.1517 |
| Invesco Ltd. | 2025-12-31 | 684,115 | 594,883 | 1.15 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 551,312 | 639,521.92 | 0.0239 |
| Advisors' Inner Circle Fund III | 2026-01-31 | I Shares | KCXIX | 899 | 1,042.84 | 0.0003 |
| VICTORY PORTFOLIOS III | 2026-01-31 | Victory Extended Market Index Fund | USMIX | 20,065 | 23,275.4 | 0.003 |
| SCHWAB CAPITAL TRUST | 2026-01-31 | Schwab Total Stock Market Index Fund | SWTSX | 90,000 | 104,400 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2026-01-31 | Fidelity ZERO Total Market Index Fund | FZROX | 83,521 | 96,884.36 | 0.0003 |